CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report

CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report


  • Products Id :- 156E4526-9F3D-41A9-95EA-D6302A593092
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

CRISPR Therapeutics-Strategy, SWOT and Corporate Finance Report

Summary

CRISPR Therapeutics-Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.

Key Highlights

CRISPR Therapeutics AG (CRISPR) is a gene editing company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human diseases. The company classifies its business into single operating segment: the business of discovering, developing and commercializing therapies derived from or incorporating genome-editing technology. Through its CRISPR/Cas9 gene-editing technology, the company allows selective deletion, modification or correction of a disease causing abnormality in a specific DNA segment. It primarily operates in Switzerland, the UK, and the US. The company is headquartered in Basel, Switzerland.

Scope

- Detailed information on CRISPR Therapeutics required for business and competitor intelligence needs

- A study of the major internal and external factors affecting CRISPR Therapeutics in the form of a SWOT analysis

- An in-depth view of the business model of CRISPR Therapeutics including a breakdown and examination of key business segments

- Intelligence on CRISPR Therapeutics's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about CRISPR Therapeutics, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of CRISPR Therapeutics and the factors that influence its strategies.

- Track strategic initiatives of the company and latest corporate news and actions.

- Assess CRISPR Therapeutics as a prospective partner, vendor or supplier.

- Support sales activities by understanding your customers' businesses better.

- Stay up to date on CRISPR Therapeutics's business structure, strategy and prospects.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Company Snapshot 2

Table of Contents 5

CRISPR Therapeutics: Company Overview 9

CRISPR Therapeutics: Overview and Key Facts 9

CRISPR Therapeutics: Overview 9

CRISPR Therapeutics: Key Facts 9

CRISPR Therapeutics: Key Employees 10

CRISPR Therapeutics: Key Employee Biographies 11

CRISPR Therapeutics: Major Products and Services 12

CRISPR Therapeutics: Company History 13

CRISPR Therapeutics: Management Statement 15

CRISPR Therapeutics: Locations and Subsidiaries 16

CRISPR Therapeutics: Key Competitors 17

CRISPR Therapeutics: Company Analysis 18

CRISPR Therapeutics: Business Description 18

CRISPR Therapeutics: SWOT Analysis 19

CRISPR Therapeutics: SWOT Overview 19

CRISPR Therapeutics: Strengths 19

CRISPR Therapeutics: Weaknesses 20

CRISPR Therapeutics: Opportunities 20

CRISPR Therapeutics: Threats 21

CRISPR Therapeutics: Corporate Financial Deals Activity 23

CRISPR Therapeutics: Financial Deals Overview 23

CRISPR Therapeutics: Targets and Partners 25

CRISPR Therapeutics: Top Deals 2014-2018YTD* 27

CRISPR Therapeutics: Advisors 28

CRISPR Therapeutics: Top Legal Advisors 28

CRISPR Therapeutics: Top Financial Advisors 28

CRISPR Therapeutics: Capital Raising 29

CRISPR Therapeutics: Partnership 30

CRISPR Therapeutics: Private Equity and Ownership 31

CRISPR Therapeutics: Recent Developments 32

CRISPR Therapeutics: News and Events Summary 32

CRISPR Therapeutics: Business Expansion 35

CRISPR Therapeutics: Corporate Governance 36

CRISPR Therapeutics: Financial Performance 36

CRISPR Therapeutics: Market Developments 36

CRISPR Therapeutics: Research & Development 39

CRISPR Therapeutics: Strategy and Operations 40

Appendix 41

Contact Us 41

Methodology 41

About MarketLine 42

List of Figures

Figure 1: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (TTM*)

Figure 2: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (2014-YTD*2018)

Figure 3: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2014-YTD*2018)

Figure 4: CRISPR Therapeutics: Capital Raising by Deal Type (2014-YTD*2018)

Figure 5: CRISPR Therapeutics: Partnership Volume and Value Trend (2014-YTD*2018)

Figure 6: CRISPR Therapeutics: Partnership Trend by Deal Type (2014-YTD*2018)

Figure 7: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2014-YTD*2018)

Figure 8: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2014-YTD*2018)

List of Tables

Table 1: CRISPR Therapeutics: Key Facts

Table 2: CRISPR Therapeutics: Key Employees

Table 3: CRISPR Therapeutics: Locations and Subsidiaries

Table 4: CRISPR Therapeutics: Key Competitors

Table 5: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (TTM*)

Table 6: CRISPR Therapeutics: Deal Activity by Deal Type-Volume (2014-YTD*2018)

Table 7: CRISPR Therapeutics: Targets and Partners

Table 8: CRISPR Therapeutics: Top Deals 2014-2018YTD*

Table 9: CRISPR Therapeutics: Legal Advisor Ranking by Value (USUSDm)

Table 10: CRISPR Therapeutics: Financial Advisor Ranking by Value (USUSDm)

Table 11: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2014-YTD*2018)

Table 12: CRISPR Therapeutics: Capital Raising by Deal Type (2014-YTD*2018)

Table 13: CRISPR Therapeutics: Partnership Volume and Value Trend (2014-YTD*2018)

Table 14: CRISPR Therapeutics: Partnership Trend by Deal Type (2014-YTD*2018)

Table 15: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2014-YTD*2018)

Table 16: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2014-YTD*2018)

Table 17: CRISPR Therapeutics: News and Events Summary

Table 18: CRISPR Therapeutics: Business Expansion

Table 19: CRISPR Therapeutics: Corporate Governance

Table 20: CRISPR Therapeutics: Financial Performance

Table 21: CRISPR Therapeutics: Market Developments

Table 22: CRISPR Therapeutics: Research & Development

Table 23: CRISPR Therapeutics: Strategy and Operations

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license
Single User License
USD 175 INR 12250
Site License
USD 350 INR 24500
Corporate User License
USD 525 INR 36750

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com